Clinical trial shows Brightseed® BioMetaControl improves glycemic control in prediabetes. Contains NCT and NFT. Study published in Bioactive Compounds in Health and Disease.
A recent clinical trial conducted in South San Francisco revealed promising results regarding the supplementation of Brightseed® BioMetaControl. The trial, which was randomized, double-blind, and placebo-controlled, demonstrated significant improvements in markers of glycemic control among adults with prediabetes. This supplement contains the natural bioactive compounds N-trans caffeoyltyramine (NCT) and N-trans feruloyltyramine (NFT). The study's findings were published in the reputable journal Bioactive Compounds in Health and Disease. Further research indicated the positive impact of this supplementation in managing prediabetes in adults.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments